<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39414823</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19.</ArticleTitle><Pagination><StartPage>8941</StartPage><MedlinePgn>8941</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-53356-5</ELocationID><Abstract><AbstractText>Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jernbom</LastName><ForeName>August F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-7773-1851</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden. august.jernbom@scilifelab.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoglund</LastName><ForeName>Lovisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0002-7863-1972</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pin</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2158-2674</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sjöberg</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1363-5796</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tegel</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7067-9173</Identifier><AffiliationInfo><Affiliation>Division of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hober</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0605-8417</Identifier><AffiliationInfo><Affiliation>Division of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostami</LastName><ForeName>Elham</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1218-6247</Identifier><AffiliationInfo><Affiliation>Section of Neurosurgery, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmusson</LastName><ForeName>Annica</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7228-7755</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Janet L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-7876-7779</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havervall</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thålin</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1345-6491</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Månberg</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0056-1313</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4657-8532</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-03063</GrantID><Agency>Vetenskapsrådet (Swedish Research Council)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018716" MajorTopicYN="N">Molecular Mimicry</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare the following competing interests: J.L.C. has received lecturing fees from Otsuka Pharma Scandinavia, Janssen-Cilag AB, and H. Lundbeck AB. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39414823</ArticleId><ArticleId IdType="pmc">PMC11484904</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-53356-5</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-53356-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol.6, eabl4340 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med.219, e20220514 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485705</ArticleId><ArticleId IdType="pubmed">36112363</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight, J. S. et al. The intersection of COVID-19 and autoimmunity. J. Clin. Invest.131, e154886 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel, A., Bastard, P., Bustamante, J. &amp; Casanova, J.-L. Human autoantibodies underlying infectious diseases. J. Exp. Med.219, e20211387 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8952682</ArticleId><ArticleId IdType="pubmed">35319722</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke, C. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav. Immun.93, 415–419 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Baiocchi, G. C. et al. Cross‐sectional analysis reveals autoantibody signatures associated with COVID‐19 severity. J. Med. Virol.95, e28538 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36722456</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevska, V. et al. Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. J. Neuroinflammation18, 245 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551937</ArticleId><ArticleId IdType="pubmed">34711233</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmenegger, M. et al. Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins. PLoS Pathog.17, e1010118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673606</ArticleId><ArticleId IdType="pubmed">34860860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J. Transl. Med.19, 524 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca, D. L. M. et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach. npj Aging9, 21 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10449916</ArticleId><ArticleId IdType="pubmed">37620330</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya, J.-M. et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J. Transl. Autoimmun.4, 100091 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920824</ArticleId><ArticleId IdType="pubmed">33681751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature595, 283–288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondt, A. et al. Human plasma IgG1 repertoires are simple, unique, and dynamic. Cell Syst.12, 1131–1143.e1135 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691384</ArticleId><ArticleId IdType="pubmed">34613904</ArticleId></ArticleIdList></Reference><Reference><Citation>Neiman, M. et al. Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity52, 1–11 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30835561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun.12, 5417 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaycox, J. R. et al. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nat. Commun.14, 1299 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9996559</ArticleId><ArticleId IdType="pubmed">36894554</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. &amp; Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis.22, e102–e107 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson, S. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA328, 1604 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. et al. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection. Mol. Med.27, 160 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686808</ArticleId><ArticleId IdType="pubmed">34930107</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux, J. et al. Autoantibodies and SARS-CoV2 infection: the spectrum from association to clinical implication: report of the 15th Dresden Symposium on Autoantibodies. Autoimmun. Rev.21, 103012 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656211</ArticleId><ArticleId IdType="pubmed">34896650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru, S. &amp; Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol.23, 194–202 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Latorre, D. Autoimmunity and SARS‐CoV‐2 infection: unraveling the link in neurological disorders. Eur. J. Immunol.52, 1561–1571 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350097</ArticleId><ArticleId IdType="pubmed">35833748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariño, H. et al. Neuroimmune disorders in COVID-19. J. Neurol.269, 2827–2839 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9120100</ArticleId><ArticleId IdType="pubmed">35353232</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera, J. A. &amp; Simon, N. M. Bridging knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19. JAMA Psychiatry79, 811 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35767287</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham, E. J. et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain145, 4097–4107 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494359</ArticleId><ArticleId IdType="pubmed">36065116</ArticleId></ArticleIdList></Reference><Reference><Citation>Prüss, H. Autoantibodies in neurological disease. Nat. Rev. Immunol.21, 798–813 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111372</ArticleId><ArticleId IdType="pubmed">33976421</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Nature623, 139–148 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober, S. et al. Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay. Clin. Transl. Immunol.10, e1312 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8288725</ArticleId><ArticleId IdType="pubmed">34295471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudberg, A.-S. et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat. Commun.11, 5064 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544689</ArticleId><ArticleId IdType="pubmed">33033249</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall, S. et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS ONE17, e0262169 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754314</ArticleId><ArticleId IdType="pubmed">35020778</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall, S. et al. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19. J. Intern. Med.291, 72–80 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661920</ArticleId><ArticleId IdType="pubmed">34459525</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlén, M. et al. The human secretome. Sci. Signal.12, eaaz0274 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31772123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernbom Falk, A. et al. Autoantibody profiles associated with clinical features in psychotic disorders. Transl. Psychiatry11, 474 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438048</ArticleId><ArticleId IdType="pubmed">34518517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature579, 265–269 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res.25, 3389–3402 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146917</ArticleId><ArticleId IdType="pubmed">9254694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky, D. S. &amp; Lipsky, P. E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol.16, 565–579 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456518</ArticleId><ArticleId IdType="pubmed">32884126</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, A. et al. Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness. JCI Insight8, e163150 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9977421</ArticleId><ArticleId IdType="pubmed">36752204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandian, A. et al. Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis. Transl. Psychiatry7, e1177 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538130</ArticleId><ArticleId IdType="pubmed">28742074</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw, E. R. et al. Temporal dynamics of anti-type 1 interferon autoantibodies in COVID-19 patients. Clin. Infect. Dis.75, e1192–e1194 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689695</ArticleId><ArticleId IdType="pubmed">34875033</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, K. G., Liu, C., Cameron, P. L. &amp; Cameron, R. S. Myr 8, a novel unconventional myosin expressed during brain development associates with the protein phosphatase catalytic subunits 1α and 1γ1. J. Neurosci.21, 7954–7968 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763852</ArticleId><ArticleId IdType="pubmed">11588169</ArticleId></ArticleIdList></Reference><Reference><Citation>Low, J. S. et al. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science377, 735–742 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348755</ArticleId><ArticleId IdType="pubmed">35857703</ArticleId></ArticleIdList></Reference><Reference><Citation>Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science377, 728–735 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348754</ArticleId><ArticleId IdType="pubmed">35857439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky, A. et al. Molecular mimicry in multisystem inflammatory syndrome in children. Nature632, 622–629 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11324515</ArticleId><ArticleId IdType="pubmed">39112696</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene, C. et al. Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat. Neurosci.27, 421–432 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlugt, C. L. &amp; Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol.2, 85–95 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11910899</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature596, 410–416 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarin, K. Y. et al. Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus. JCI Insight9, e176556 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10972586</ArticleId><ArticleId IdType="pubmed">38456511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen, I. B. et al. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin. Endocrinol.58, 36–42 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12519410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, S. H. et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw. Open6, e2336120–e2336120 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10559181</ArticleId><ArticleId IdType="pubmed">37801317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch, F. et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin. Rheumatol.42, 2905–2914 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10497688</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell184, 92–105.e116 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584921</ArticleId><ArticleId IdType="pubmed">33147445</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Dorival, I. et al. Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Res.194, 105167 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8382594</ArticleId><ArticleId IdType="pubmed">34450201</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, I. et al. Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1. Nat. Commun.15, 162 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10762260</ArticleId><ArticleId IdType="pubmed">38167417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky, A. et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight8, e169515 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Just, D. et al. Autoantibodies against the C-terminus of lipopolysaccharide binding protein are elevated in young adults with psychiatric disease. Psychoneuroendocrinology126, 105162 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33578084</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill.25, 2000045 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar, J. et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur. J. Neurol.28, 3324–3331 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund, L. et al. A whole-genome bioinformatics approach to selection of antigens for systematic antibody generation. Proteomics8, 2832–2839 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18655051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pin, E. et al. in Cerebrospinal Fluid (CSF) Proteomics: Methods and Protocols (eds Santamaría, E. &amp; Fernández-Irigoyen, J.) ch 19 (Springer, 2019).</Citation></Reference><Reference><Citation>Schubert, E. &amp; Rousseeuw, P. J. Fast and eager k-medoids clustering: O(k) runtime improvement of the PAM, CLARA, and CLARANS algorithms. Inform. Syst.101, 101804 (2021).</Citation></Reference><Reference><Citation>Jernbom, A. F. abtract v0.1.0. Zenodo10.5281/zenodo.13882631 (2024).</Citation></Reference><Reference><Citation>Venables, W. N. &amp; Ripley, B. D. Modern Applied Statistics with S-Plus 4th edn. (Springer, 2002).</Citation></Reference><Reference><Citation>Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw.28, 1–26 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, P. D. et al. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci.31, 8–22 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8740835</ArticleId><ArticleId IdType="pubmed">34717010</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbon, S. et al. AmiGO: online access to ontology and annotation data. Bioinformatics25, 288–289 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639003</ArticleId><ArticleId IdType="pubmed">19033274</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbon, S. &amp; Mungall, C. Gene ontology data archive. Zenodo10.5281/zenodo.10536401 (2024).</Citation></Reference><Reference><Citation>Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. SciLifeLab Data Repository10.17044/scilifelab.26318929.v1 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11484904</ArticleId><ArticleId IdType="pubmed">39414823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>